Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1503
Shown on this page
12
Current sort
Recently updated
Campus scope
Duke University Medical Center, Durham, NC
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Duke University Medical Center, Durham, NC. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 757–768 of 1,503 matching trials with a site at Duke University Medical Center, Durham, NC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

NCT07354724
Status at this site: Recruiting
View directory record Official record
Conditions
Late-onset Pompe Disease
Interventions
DNL952
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Irvine, California • St Louis, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting Phase 2 Interventional

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
FG-3246
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Active, not recruiting Not applicable Interventional

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

NCT06685848
Site status not listed — check the official record
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Hemanext ONE system, Conventional RBCs
Device
Lead sponsor
Hemanext
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Active, not recruiting Phase 2 Interventional Results available

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481
Site status not listed — check the official record
View directory record Official record
Conditions
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Interventions
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting Not applicable Interventional

Alleviant ALLAY-HF Study

NCT05685303
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure
Interventions
Alleviant ALV1 System, Sham-Control
Device · Other
Lead sponsor
Alleviant Medical, Inc.
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors Harboring MET Amplification
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Active, not recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257
Site status not listed — check the official record
View directory record Official record
Conditions
Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Interventions
Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
125
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510
Site status not listed — check the official record
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Active, not recruiting Phase 3 Interventional

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Myelofibrosis, Myeloproliferative Neoplasm
Interventions
Ropeginterferon alfa-2b, Placebo
Biological · Other
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting No phase listed Observational

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

NCT01915511
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting Not applicable Interventional

Behavioral Pain Intervention for Older Cancer Patients

NCT07300995
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
Pain Coping Skills Training (PCST)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
55 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 2:41 PM EST
Recruiting Phase 2 Interventional

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

NCT05489887
Status at this site: Recruiting
View directory record Official record
Conditions
Neuroblastoma
Interventions
Naxitamab
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 21 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 2:41 PM EST

About this Duke University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Duke University at any site, browse by condition, or browse by U.S. city.